AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 28864284
Drug: Caffeine-containing analgesics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine-containing analgesics (300 mg acetaminophen and 20 mg caffeine)
Trial: 28864284
Drug: Codeine-containing analgesics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Codeine-containing analgesics (300 mg acetaminophen and 20 mg codeine)
Trial: 25261399
Drug: 0.4 %
RxNorm normalized name: oxygen 20.4 %
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 % stannous fluoride gel and a crème containing 10 % CPP‐ACP applied three times daily and fluoride gel once daily
Trial: 25261399
Drug: Similar crème
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Similar crème without CPP‐ACP applied three times daily and fluoride gel once daily
Trial: 24293993
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 1800 mg
Trial: 9673532
Drug: L-carnitine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine treatment (20 mg/kg intravenously at the end of each hemodialysis session)
Trial: 8033496
Drug: DuP 128
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DuP 128 (900 mg per day)
Trial: 8033496
Drug: DuP 128
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DuP 128 (1800 mg per day)
Trial: 8033496
Drug: DuP 128
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DuP 128 (3600 mg per day)
Trial: 8033496
Drug: Neomycin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neomycin (1 gm twice a day)
Trial: 1092282
Drug: Amitriptyline hydrochloride
RxNorm normalized name: Amitriptyline Hydrochloride
DrugBank: Amitriptyline (DB00321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amitriptyline hydrochloride with marital therapy
Trial: 1092282
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with marital therapy
Trial: 30741469
Drug: Maxillary implant
RxNorm normalized name: Artemisia capillaris leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maxillary implant overdentures on solitary attachments (group I)
Trial: 30741469
Drug: Maxillary implant
RxNorm normalized name: Artemisia capillaris leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maxillary implant overdentures on bars (group II)
Trial: 28011037
Drug: Lumacaftor 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lumacaftor 400 mg every 12 h / Ivacaftor 250 mg every 12 h
Trial: 28011037
Drug: Lumacaftor 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lumacaftor 600 mg once daily / Ivacaftor 250 mg every 12 h
Trial: 21654350
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg 4 times daily
Trial: 17178957
Drug: Cefuroxime (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefuroxime (1.5 g IV)
Trial: 17178957
Drug: Ampicillin-sulbactam (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ampicillin-sulbactam (3 g IV)
Trial: 12753318
Drug: Pamidronate (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamidronate (0.5 mg/kg) given at the time of transplantation and 1 month later
Trial: 10618584
Drug: ACE inhibitor
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitor alone (captopril)
Trial: 6631616
Drug: self-administered questionnaire
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: self-administered questionnaire
Trial: 17697141
Drug: Low doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low doses of aspirin
Trial: 8393509
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of oral azathioprine and methotrexate and high-dose intravenous methotrexate with leucovorin rescue
Trial: 3034018
Drug: Hydrochlorothiazide (concomitant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (concomitant treatment for nonresponders)
Trial: 15662290
Drug: Trimetazidine (TMZ)
RxNorm normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimetazidine (TMZ) 20 mg t.i.d.
Trial: 10233186
Drug: bosentan 700
RxNorm normalized name: Bosentan
DrugBank: Bosentan (DB00559)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: bosentan 700 mg
Trial: 10233186
Drug: misoprostol 400
RxNorm normalized name: Misoprostol 400 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: misoprostol 400 mg
Trial: 8904256
Drug: High-dose vecuronium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose vecuronium (0.3 mg kg‐1)
Trial: 29555790
Drug: Chlorothiazide 500
RxNorm normalized name: chlorothiazide 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorothiazide 500 mg
Trial: 19663893
Drug: Continued low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Continued low-dose steroids
Trial: 19663893
Drug: Steroid withdrawal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid withdrawal and continued low-dose steroids
Trial: 17008577
Drug: Staged care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Staged care intervention participants received computerized motivational feedback at baseline and at 3, 6, and 12 months, and were offered a 6-session psychological counseling and pharmacological cessation treatment program.
Trial: 17008577
Drug: Brief contact
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brief contact control participants received a self-help guide and referral list of local smoking-treatment providers.
Trial: 14574348
Drug: almond‐LCD (84
FDA approved: no
EMA approved: no
PMDA approved: no
Description: almond‐LCD (84 g/day of almonds, 39% total fat, 25% MUFA, 32% carbohydrate)
Trial: 14574348
Drug: almond‐LCD (84
FDA approved: no
EMA approved: no
PMDA approved: no
Description: almond‐LCD (84 g/day of almonds)
Trial: 31382210
Drug: TENS (pulse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TENS (pulse of 200 μs, frequency at 10 Hz, in motor threshold) for 20 min followed by 30 min of vocal therapy
Trial: 31382210
Drug: Placebo TENS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo TENS for 20 min followed by 30 min of vocal therapy
Trial: 18818443
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg of donepezil (Aricept) daily for 6 weeks, increased to 10 mg daily for another 6 weeks, followed by cognitive training for 2 weeks and maintained for 1 year
Trial: 18818443
Drug: Placebo daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo daily for 6 weeks, followed by cognitive training for 2 weeks and maintained for 1 year
Trial: 11994052
Drug: Metformin (1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (1500 mg day-1)
Trial: 11994052
Drug: Clomiphene (50-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clomiphene (50-100 mg for 5 days) with Metformin
Trial: 11994052
Drug: Clomiphene (50-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clomiphene (50-100 mg for 5 days) with Placebo
Trial: 7772427
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid 15 mg kg‐1
Trial: 442002
Drug: Intraderma injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraderma injection of a suspension of irradiated autologous tumour-cells mixed with intradermal BCG
Trial: 21860157
Drug: Topical 5%
RxNorm normalized name: urea topical 5% topical lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 5% permethrin (group A)
Trial: 21860157
Drug: Oral ivermectin
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ivermectin (200 μg/kg/dose) in a single dose (group B)
Trial: 21860157
Drug: Oral ivermectin
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ivermectin (200 μg/kg/dose) in a double dose regimen (group C)
Trial: 19462326
Drug: Flavor-enhanced tomato
RxNorm normalized name: Tomato
DrugBank: Tomato (DB10573)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flavor-enhanced tomato soup (1,200 mg/l MSG + 3 g/l celery powder)
Trial: 16946093
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of 100 microg LPS
Trial: 10924300
Drug: Intravenous sotalol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous sotalol (1.5 mg. kg(‐1))
Trial: 8644832
Drug: Activity-based therapy
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activity-based therapy regimen (30 min each day)
Trial: 31213572
Drug: Individual inhalation
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individual inhalation training (study group)
Trial: 24201696
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo daily for 20 weeks
Trial: 22776627
Drug: No helmet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No helmet therapy
Trial: 7593436
Drug: Sandostatin-LAR (20,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sandostatin-LAR (20, 30, or 40 mg) administered via intramuscular injections at 28- or 42-day intervals
Trial: 26150412
Drug: SCAMP (30%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCAMP (30% more parenteral nutrition amino acids)
Trial: 26150412
Drug: Control parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control parenteral nutrition regimen
Trial: 11899783
Drug: Vinorelbine in
RxNorm normalized name: vinorelbine Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinorelbine in combination with trastuzumab and newer molecular targeting agents
Trial: 11899783
Drug: Vinorelbine in
RxNorm normalized name: vinorelbine Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinorelbine in doublets or triplets with drugs other than anthracyclines and taxanes
Trial: 9272782
Drug: Morphine test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine test
Trial: 9272782
Drug: Chronic motor
RxNorm normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronic motor cortex stimulation therapy
Trial: 7881144
Drug: 20 mL
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL of bupivacaine during both S1 and S2 (Group C)
Trial: 7881144
Drug: 20 mL
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL of saline during S1 and S2 (Group A)
Trial: 7881144
Drug: 20 mL
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL of saline during S1 and 20 mL of bupivacaine during S2 (Group B)
Trial: 26068297
Drug: Intermittent PTH
RxNorm normalized name: PTH
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intermittent PTH administration (iPTH)
Trial: 23587982
Drug: Desvenlafaxine 25
RxNorm normalized name: DESVENLAFAXINE 25 mg ORAL TABLET, EXTENDED RELEASE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desvenlafaxine 25 mg/day (initial dose), titrated to a maximum of 100 mg/day based on clinical response
Trial: 23587982
Drug: Desvenlafaxine (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desvenlafaxine (various doses)
Trial: 21693027
Drug: Culturally adapted
RxNorm normalized name: casein, emmental cultured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Culturally adapted Problem Solving Therapy (C-MAP), 8 sessions lasting approximately 50 minutes each over 3 months
Trial: 20015817
Drug: Removal of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Removal of the catheter after discontinuation of PCEA (Group 2)
Trial: 16230866
Drug: BNP-guided up-titration
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNP-guided up-titration of beta blocker
Trial: 12746760
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg Pioglitazone once daily
Trial: 7503047
Drug: High intake
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High intake of vitamin C and beta-carotene (mean intakes: 138 mg/day vitamin C, 5.3 mg/day beta-carotene)
Trial: 24074457
Drug: Intranasal inhalation
RxNorm normalized name: NALOXONE RESCUE KIT INTRANASAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal inhalation of 24 IU of oxytocin
Trial: 20197785
Drug: A. bisporus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A. bisporus alpha‐glucans (5 g glucans/day)
Trial: 20197785
Drug: Control fruit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control fruit juice (200 ml/day)
Trial: 17628352
Drug: Reserpine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reserpine (0.5 mg/day)
Trial: 16376736
Drug: Conversations about
RxNorm normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conversations about treatment preferences
Trial: 10205584
Drug: Bedtime uncooked
RxNorm normalized name: Buckley's Bedtime Formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bedtime uncooked cornstarch (0.3 g kg‐1 body weight)
Trial: 10205584
Drug: Conventional snack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional snack (wholemeal bread, 0.6 g of carbohydrates kg‐1 body weight)
Trial: 417644
Drug: L-amino acid
RxNorm normalized name: L-α-amino-γ-methylmercaptobutyric acid
DrugBank: Methionine (DB00134)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-amino acid solutions (0.24 g N/kg body weight/day) + glucose and fructose
Trial: 417644
Drug: L-amino acid
RxNorm normalized name: L-α-amino-γ-methylmercaptobutyric acid
DrugBank: Methionine (DB00134)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-amino acid solutions (0.24 g N/kg body weight/day) + glucose, fructose, and fat emulsions (30-40% of total calories, 30 kcal/kg body weight/day)
Trial: 31876947
Drug: Group cognitive
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group cognitive behavioral therapy for chronic pain
Trial: 31876947
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (taper only)
Trial: 27324506
Drug: LCZ696 (sacubitril/valsartan)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCZ696 (sacubitril/valsartan) 20-600 mg
Trial: 27324506
Drug: LCZ696 (sacubitril/valsartan)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCZ696 (sacubitril/valsartan) 200 mg with food
Trial: 26688235
Drug: Methotrexate (3.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate (3.5 g/m²) with temozolomide (150 mg/m²)
Trial: 26688235
Drug: Methotrexate (3.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate (3.5 g/m²), procarbazine (100 mg/m²), vincristine (1.4 mg/m²), and cytarabine (3 mg/m²)
Trial: 23421759
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (20 mg daily for 12 months)
Trial: 23421759
Drug: Placebo (lactose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (lactose monohydrate and stearic acid, same weight as zinc capsules)
Trial: 16601659
Drug: Genital ulcer
RxNorm normalized name: adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Genital ulcer treatment in the last year
Trial: 25085275
Drug: GS 500
RxNorm normalized name: acetaminophen/herbal drugs 500 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GS 500 mg/CS 400 mg three times daily capsules (GI)
Trial: 25085275
Drug: GS 500
RxNorm normalized name: acetaminophen/herbal drugs 500 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GS 500 mg/CS 400 mg once daily sachet (GII)
Trial: 25085275
Drug: GH 500
RxNorm normalized name: FUSION PROTEIN OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG- .BETA.)-(118-145)-PEPTIDE (1-28) WITH HUMAN SOMATOTROPIN (GROWTH HORMONE, GH) (29-219) AND TWO TANDEM COPIES OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG-.BETA.)-(118-145)- PEPTIDE (220-247
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH 500 mg/CS 400 mg three times daily (GIII)
Trial: 23588112
Drug: Growth-arrested neonatal
RxNorm normalized name: Foreskin fibroblast (neonatal)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth-arrested neonatal dermal fibroblasts and keratinocytes delivered via pump spray in a fibrin sealant-based matrix, plus a foam dressing and four-layer compression bandaging for 12 weeks or until healed.
Trial: 23588112
Drug: Vehicle control
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle control (no active treatment).
Trial: 21915478
Drug: L-thyroxine replacement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-thyroxine replacement
Trial: 17029610
Drug: Peginterferon alfa-2b
RxNorm normalized name: Peginterferon alfa-2b
DrugBank: Peginterferon alfa-2b (DB00022)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Peginterferon alfa-2b (100 microg weekly for 52 weeks)
Trial: 28238203
Drug: JNJ‐53718678 (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ‐53718678 (single doses of 25-1000 mg)
Trial: 28238203
Drug: JNJ‐53718678 (multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ‐53718678 (multiple doses of 250 mg every 24 h, 500 mg q24h, 250 mg every 12 h for 8 days)
Trial: 20215977
Drug: Estrogen therapy
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen therapy (ET) - conjugated equine estrogens 0.625 mg daily
Trial: 20215977
Drug: Estrogen +
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen + progesterone therapy (EPT) - ET plus medroxyprogesterone acetate 2.5 mg daily
Trial: 10445673
Drug: Levosimendan (18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levosimendan (18 or 36 microg/kg loading dose and 0.2 or 0.3 microg/kg/min infusion)
Trial: 10445673
Drug: Levosimendan (high-dose)
RxNorm normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levosimendan (high-dose)
Trial: 15025738
Drug: Levosimendan (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levosimendan (both doses)
Trial: 316786
Drug: Portacaval shunt
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Portacaval shunt surgical treatment
Trial: 316786
Drug: No surgical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No surgical treatment (control)
Trial: 6354422
Drug: Superfractionation (SF)
RxNorm normalized name: light green SF yellowish
DrugBank: Light green SF yellowish (DB11183)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Superfractionation (SF) radiation therapy (4000 rad in 45 fractions in 3 weeks whole brain and 1000 rad in five fractions in one week local boost)
Trial: 6354422
Drug: Conventional Fractionation
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional Fractionation (CF) radiation therapy (3400 rad in 17 fractions whole brain in 3.5 weeks and 1600 rad in eight fractions in 1.5 weeks local boost)
Trial: 6354422
Drug: Superfractionation (SF)
RxNorm normalized name: light green SF yellowish
DrugBank: Light green SF yellowish (DB11183)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Superfractionation (SF) radiation therapy
Trial: 31282028
Drug: Placebo (plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (plus standard of care therapy)
Trial: 29432959
Drug: 12 SQ‐HDM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 SQ‐HDM (sublingual immunotherapy tablet)
Trial: 24128654
Drug: Salmon consumption
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmon consumption (two 150 g portions of farmed salmon per week from 20 weeks of pregnancy to delivery)
Trial: 22397774
Drug: Intrarectal gel
RxNorm normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrarectal gel instillation
Trial: 18629526
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg venlafaxine
Trial: 11882931
Drug: r‐HuEPO+intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: r‐HuEPO+intravenous iron (EPO+IV)
Trial: 11882931
Drug: r‐HuEPO+oral iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: r‐HuEPO+oral iron (EPO+OR)
Trial: 10531077
Drug: DMARD and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMARD and prednisolone (mean dose 6 mg, mean cumulated dose 2160 mg)
Trial: 7789045
Drug: Inhibition of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhibition of angiotensin-converting enzyme (lisinopril)
Trial: 2112177
Drug: Flumazenil (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flumazenil (0.5 to 1.0 mg)
Trial: 30327952
Drug: Brush-off patch
RxNorm normalized name: Off! Explore
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brush-off patch containing 3.0% hydrogen peroxide applied for 10 min twice daily (case 10 group)
Trial: 30327952
Drug: Brush-off patch
RxNorm normalized name: Off! Explore
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brush-off patch containing 3.0% hydrogen peroxide applied for 30 min once daily (case 30 group)
Trial: 26918556
Drug: Miglitol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Miglitol (50 mg) just before breakfast (intake schedule B)
Trial: 26918556
Drug: Miglitol dissolved
RxNorm normalized name: Miglitol
DrugBank: Miglitol (DB00491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Miglitol dissolved in water (50 mg) taken just before, during, and just after breakfast (intake schedule C)